Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Using stress testing to guide primary prevention of coronary heart disease among intermediate-risk patients: a cost-effectiveness analysis.

Galper BZ, Moran A, Coxson PG, Pletcher MJ, Heidenreich P, Lazar LD, Rodondi N, Wang YC, Goldman L.

Circulation. 2012 Jan 17;125(2):260-70. doi: 10.1161/CIRCULATIONAHA.111.041293. Epub 2011 Dec 5.

3.

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.

Pignone M, Earnshaw S, Tice JA, Pletcher MJ.

Ann Intern Med. 2006 Mar 7;144(5):326-36.

PMID:
16520473
4.

Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.

Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L.

Ann Intern Med. 2009 Feb 17;150(4):243-54.

PMID:
19221376
5.

Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis.

Pletcher MJ, Pignone M, Earnshaw S, McDade C, Phillips KA, Auer R, Zablotska L, Greenland P.

Circ Cardiovasc Qual Outcomes. 2014 Mar;7(2):276-84. doi: 10.1161/CIRCOUTCOMES.113.000799. Epub 2014 Mar 11.

6.

Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.

Choudhry NK, Patrick AR, Antman EM, Avorn J, Shrank WH.

Circulation. 2008 Mar 11;117(10):1261-8. doi: 10.1161/CIRCULATIONAHA.107.735605. Epub 2008 Feb 19.

7.

Summaries for patients. The cost-effectiveness of aspirin, statins, or both drugs in the primary prevention of heart disease.

[No authors listed]

Ann Intern Med. 2006 Mar 7;144(5):I29. No abstract available.

PMID:
16520469
8.

Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence--estimates from the Finnish prescription register.

Aarnio E, Korhonen MJ, Huupponen R, Martikainen J.

Atherosclerosis. 2015 Mar;239(1):240-7. doi: 10.1016/j.atherosclerosis.2014.12.059. Epub 2015 Jan 14.

PMID:
25618032
9.

Cost-effectiveness of optimal use of acute myocardial infarction treatments and impact on coronary heart disease mortality in China.

Wang M, Moran AE, Liu J, Coxson PG, Heidenreich PA, Gu D, He J, Goldman L, Zhao D.

Circ Cardiovasc Qual Outcomes. 2014 Jan;7(1):78-85. doi: 10.1161/CIRCOUTCOMES.113.000674. Epub 2014 Jan 14.

10.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

11.

Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.

Fidan D, Unal B, Critchley J, Capewell S.

QJM. 2007 May;100(5):277-89. Epub 2007 Apr 21.

PMID:
17449875
12.
13.

Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA).

Roberts ET, Horne A, Martin SS, Blaha MJ, Blankstein R, Budoff MJ, Sibley C, Polak JF, Frick KD, Blumenthal RS, Nasir K.

PLoS One. 2015 Mar 18;10(3):e0116377. doi: 10.1371/journal.pone.0116377. eCollection 2015.

14.

Statins for cardiovascular prevention according to different strategies: a cost analysis.

Ito MK, Nanchen D, Rodondi N, Paccaud F, Waeber G, Vollenweider P, Marques-Vidal P.

Am J Cardiovasc Drugs. 2011;11(1):33-44. doi: 10.2165/11586760-000000000-00000.

PMID:
21265581
15.

Is it cost-effective to use a test to decide which individuals with an intermediate cardiovascular disease risk would benefit from statin treatment?

Burgers LT, Nauta ST, Deckers JW, Severens JL, Redekop WK.

Int J Cardiol. 2014 Oct 20;176(3):980-7. doi: 10.1016/j.ijcard.2014.08.134. Epub 2014 Sep 2.

PMID:
25217221
16.

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.

Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC.

Ann Intern Med. 2000 May 16;132(10):769-79.

PMID:
10819699
17.

Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland.

Barry M, Heerey A.

Ir Med J. 2002 May;95(5):133-5. No abstract available.

PMID:
12092692
18.

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.

Gaspoz JM, Coxson PG, Goldman PA, Williams LW, Kuntz KM, Hunink MG, Goldman L.

N Engl J Med. 2002 Jun 6;346(23):1800-6.

19.

Cost-effectiveness of diagnostic strategies for patients with chest pain.

Kuntz KM, Fleischmann KE, Hunink MG, Douglas PS.

Ann Intern Med. 1999 May 4;130(9):709-18.

PMID:
10357689
20.

Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis.

Greving JP, Visseren FL, de Wit GA, Algra A.

BMJ. 2011 Mar 30;342:d1672. doi: 10.1136/bmj.d1672.

Supplemental Content

Support Center